SPRO
Spero TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade F from latest DB weights. Momentum 5.3 / Value 55.8
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.4.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
5
Value
56
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $4.00
Why
Momentum5 · Δ7d -
Value56 · Δ7d +0.4
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
5
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
56
60% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+1.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 5.3 / Value 55.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$83.38M
Beta
1.45
Shares Out
57.9M
P/E (TTM) · Derived
9.4
P/S (TTM)
3.38
P/FCF (TTM) · Derived
11.08
Rev YoY
-95.0%
EPS YoY
-49.8%
Gross Margin
+99.1%
Op Margin
-115.5%
Net Debt
-$37.37M
Current Ratio
10.50
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology